Arvinas regains investor confidence with path forward for androgen-receptor degrader, second proof of concept for platform

A better understanding of responder profiles, a path to accelerated approval and proof that its degrader platform is not a one-trick pony were among the factors that nearly doubled Arvinas’ stock after the company presented interim data to investors Monday.

Shares of Arvinas Inc. (NASDAQ:ARVN) gained $28.45 (95%) to $58.38, an all-time high that completed the stock’s rebound from the hit they took after the company presented data at the American Society of Clinical Oncology meeting in May. The company finished the week raising $400 million in a follow-on, with its shares up 130% at $68.95, for a market cap of $3.3 billion. ...